1. Home
  2. ADCT vs NKLR Comparison

ADCT vs NKLR Comparison

Compare ADCT & NKLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.13

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

NKLR

Terra Innovatum Global N.V. Ordinary shares

HOLD

Current Price

$4.85

Market Cap

500.6M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADCT
NKLR
Founded
2011
2018
Country
Switzerland
Italy
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
431.2M
500.6M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ADCT
NKLR
Price
$1.13
$4.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$7.75
$15.00
AVG Volume (30 Days)
3.3M
287.9K
Earning Date
05-04-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
30.86
N/A
EPS
N/A
N/A
Revenue
$81,357,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$66.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.85
N/A
52 Week Low
$0.78
$3.73
52 Week High
$4.98
$12.43

Technical Indicators

Market Signals
Indicator
ADCT
NKLR
Relative Strength Index (RSI) 27.44 43.07
Support Level $0.78 $3.94
Resistance Level $1.17 $5.25
Average True Range (ATR) 0.10 0.40
MACD 0.08 -0.01
Stochastic Oscillator 77.38 42.40

Price Performance

Historical Comparison
ADCT
NKLR

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About NKLR Terra Innovatum Global N.V. Ordinary shares

Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.

Share on Social Networks: